{"brief_title": "Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)", "brief_summary": "This study will compare 2 treatments in the way they affect cholesterol levels and the amount of HIV in the blood.", "detailed_description": "The study is designed to determine the metabolic changes, antiviral activity, safety, and tolerability of atazanavir as compared to LPV/RTV, each in combination with 2 nucleosides, over the initial 24 weeks, with a final analysis at 48 weeks.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Lopinavir/Ritonavir", "criteria": "Inclusion Criteria Patients may be eligible for this study if they: - Are receiving a PI-containing highly active antiretroviral therapy (HAART) for at least 12 weeks. - Have a viral load of 1,000 or more copies/ml within 4 weeks of screening and within 4 weeks prior to randomization. - Have 2 CD4 cell counts of 50 or more cells/mm3 at least 96 hours apart and within 4 weeks before randomization. - Are at least 16 years old. - Have a documented virologic response to at least 1 HAART regimen. - Have phenotypic sensitivity to at least 2 of the following: ddl, d4T, ZDV, 3TC, ABC. - Have phenotypic sensitivity to atazanavir and LPV/RTV. - Use effective barrier methods of birth control. - Will be available for 48 weeks. Exclusion Criteria Patients will not be eligible for this study if they: - Have taken 2 or more PIs and had virologic failure. - Have taken atazanavir or LPV/RTV. - Have an HIV-related infection (within 30 days) or any medical condition requiring treatment at the time of enrollment. - Have had acute hepatitis in the 30 days prior to study entry. - Have received certain drugs within 3 months of study start or expect to need them at time of enrollment. - Abuse alcohol or drugs in a way that would interfere with the study. - Have very bad diarrhea within 30 days prior to study entry. - Are pregnant or breast-feeding. - Have a history of hemophilia. - Use lipid-lowering drugs (within the previous 30 days). - Have cardiomyopathy or symptoms of other heart disease. - Cannot take medicine by mouth. - Have any other condition that would interfere with the study. - Have pancreatitis, if choosing ddI as part of NRTI pair. - Have bilateral peripheral neuropathy at time of screening, if choosing ddI or or d4T as part of the NRTI pair.", "gender": "All", "minimum_age": "16 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00028301.xml"}